PAVmed: A Small Cap Puts Its Streamlined Development Model to the Test

article image

Getting Wall Street to pay attention to micro- and small-cap companies like PAVmed is difficult, particularly in the medtech field. But with the pending IPO of its Lucid subsidiary and formation of a new one focused on digital health, the company, which has a streamlined model for device innovation, has a near-term opportunity to raise its profile.

About seven years ago, the cardiothoracic surgeons and former colleagues Lishan Aklog, MD, and Brian DeGuzman, MD, along with Michael Glennon, an experienced medical device executive, decided to form a company devoted to medical device innovation, building on Pavilion Holdings Group, an earlier successful venture they had started in 2008. They formed PAVmed Inc. to develop innovative devices and start-ups based on a fast-to-market, capital efficient business model.


This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.



We're here to help! Please contact us at: